Here's the scoop on Celladon as of 5/8/2015....
Celladon is a R&D pharmaceutical company whose lead candidate is Mydicar, a drug which modifies genes via a viral vector. The hope was the drug would increase calcium in the heard and reduce future incidents of heart failure. Phase 2A trials were highly promising and the FDA gave the drug a breakthrough therapy designation.
When phase 2B results came out April 27, the trial failed. The stock naturally was hammered.
The company said it would review the results and establish whether the drug delivered the necessary changes to the heart tissue over the next month.
So that's where the company sits currently. The company has a negative enterprise value because there is more cash on the books than the company's market cap plus debt. However just because there's more cash than the company is worth doesn't may not necessarily mean there's a backstop to the stock price. The company will have ongoing expenses which will eat into that.
So where does the company go from here?? It seems that the company did great work in developing the drug...even if they might have fallen flat designing the trial. There's a lot of cash on the books. That seems positive. On the negative potential column, the company might just eat away at the cash for the next couple of years until that cash is gone.
Celladon is a R&D pharmaceutical company whose lead candidate is Mydicar, a drug which modifies genes via a viral vector. The hope was the drug would increase calcium in the heard and reduce future incidents of heart failure. Phase 2A trials were highly promising and the FDA gave the drug a breakthrough therapy designation.
When phase 2B results came out April 27, the trial failed. The stock naturally was hammered.
The company said it would review the results and establish whether the drug delivered the necessary changes to the heart tissue over the next month.
So that's where the company sits currently. The company has a negative enterprise value because there is more cash on the books than the company's market cap plus debt. However just because there's more cash than the company is worth doesn't may not necessarily mean there's a backstop to the stock price. The company will have ongoing expenses which will eat into that.
So where does the company go from here?? It seems that the company did great work in developing the drug...even if they might have fallen flat designing the trial. There's a lot of cash on the books. That seems positive. On the negative potential column, the company might just eat away at the cash for the next couple of years until that cash is gone.
Celladon Corp (CLDN) Stock Research Links
Yes, I understand your penny stock also is the real deal, created with the inventiveness of Edison and destined to be the next Microsoft. Yes, I understand that the delays are also only because your company is making their product and/or technology even more revolutionary.
